Navigation Links
DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers

DETROIT, Sept. 15 /PRNewswire-USNewswire/ -- Researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine have developed a HER2 DNA vaccine that has shown to be effective on drug resistant tumors in mice. The study was reported in the September 15 issue of Cancer Research, a journal of the American Association for Cancer Research.

( GO)

Wei-Zen Wei, Ph.D., professor at the Barbara Ann Karmanos Cancer Institute and Department of Immunology and Microbiology, Wayne State University School of Medicine, together with a team of researchers have been working on a series of cancer-fighting vaccines since 1996 to help prevent HER2-positive breast cancer.

Approximately 20 - 30 percent of breast cancers make too much of the protein called HER2, which is made at low levels by normal breast cells. Tumors that overexpress HER2 (called HER2-positive) tend to grow faster and are more likely to come back than tumors that don't overexpress the protein.

According to Dr. Wei, this HER2 DNA vaccine was tested in the laboratory on tumor cells that no longer responded to other therapies for HER2-positive breast cancer. The results in mice showed that the vaccine prevented the cancer from growing and was not toxic.

"We each have an immune system to help fight off disease," explained Dr. Wei. "However, when cancer develops, the immune system can't always distinguish tumor cells from normal cells, so the full power of the immune system is not harnessed to fight the disease. This vaccine helps to educate the immune system so that it recognizes HER2-positive cancer cells, helps destroy them and prevents them from spreading."

Dr. Wei's lab is the first to develop HER2 DNA vaccines. The first vaccine was developed in 1999. In collaboration with the Karolinska Institute in Stockholm, Sweden, a pilot clinical trial with the HER2 DNA vaccine has been conducted in patients with Stage IV breast cancer and has demonstrated safety. Further testing is being considered.

Dr. Wei added, "As we continue our extensive research on this promising vaccine, based on the results to-date, we believe this could eventually help control the spread of HER2-positive breast cancer in patients who have been resistant to other treatments, and possibly prevent HER2-positive breast cancer from occurring."

Other researchers working with Dr. Wei include: Paula J. Whittington, Marie P. Piechocki, Henry H. Heng, Jennifer B. Jacob, Richard F. Jones and Jessica B. Back.

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to

SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
8. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
Post Your Comments:
(Date:11/30/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... Free Press as a Top Workplace , among the ... work for in 2015. ... annually, based on employee surveys rating company leadership, career opportunities, ... based solely on employee feedback. The survey is conducted by ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... An ... directory is specialized and only includes chiropractic clinics in the US. , The ... trustworthy alternative health practitioner when back pain sets in. When people are experiencing ...
(Date:11/30/2015)... ... November 30, 2015 , ... In ... Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted a ... a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced that the ... ointment to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s ... the comparison chart and ingredient list allows our customers to quickly see why, ...
Breaking Medicine News(10 mins):